Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL S versus PROMAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL S versus PROMAZINE HYDROCHLORIDE.
MELLARIL-S vs PROMAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, also exhibiting alpha-adrenergic blockade and anticholinergic effects.
Promazine hydrochloride is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, as well as histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors. It also has moderate serotonin and weak serotonin-dopamine antagonist effects.
Initial 50-100 mg orally 3 times daily, titrate to 200-600 mg/day in divided doses; maximum 800 mg/day for severe psychosis.
25-50 mg intramuscularly every 4-6 hours as needed. Maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10–20 hours (mean ~15 hours). Clinical context: Steady-state achieved within 4–5 days; allows once-daily or twice-daily dosing.
Terminal elimination half-life: 12-18 hours; in elderly or hepatic impairment may extend to 30 hours
Primarily renal (approximately 70%) as metabolites (sulfoxides and glucuronides); about 30% excreted in feces via bile. Less than 1% excreted unchanged.
Primarily renal (approx. 70-80% as metabolites, <1% unchanged); minor biliary/fecal (approx. 15-20%)
Category C
Category C
Antipsychotic
Antipsychotic